-+ 0.00%
-+ 0.00%
-+ 0.00%

Pacira BioSciences Enters Into Agreement With LG Chem To Expand Access To Opioid-Sparing Postsurgical Pain Control For Patients In Select Asian-Pacific Markets

Benzinga·01/13/2026 13:02:01
Listen to the news

-- LG Chem becomes exclusive distributor of EXPAREL -- 

– Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–

BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-acting, local analgesic for postsurgical pain management in the region.